Abstract
Purpose: To classify patients with advanced hepatocellular carcinoma (HCC) who might benefit from locoregional therapies. Materials and methods: Data of 62 patients with advanced HCC from 11/2020 to 08/2022 at Hue University of Medicine and Pharmacy Hospital were analyzed. Computed tomography (CT) findings, all liver function tests and performance status (PS) were documented. Criteria for considering locoregional therapies include tumor size ≤ 10 cm, segmental portal vein thrombosis, Child-Pugh A and PS 0 - 1. Results: Mean age: 59.4 ± 11 years, male: female ratio 9:1. Average tumor size: 10.2 ± 4.2 cm. 64.5% of patients had PS 0 - 1; 69.4% had Child-Pugh A; 59.7% had ALBI grade 2. There was a positive correlation between ALBI score and Child-Pugh score (p < 0.01). ECOG PS was associated with Child-Pugh classification (p < 0.01) and ALBI grade (p < 0.01). There was an association between portal vein thrombosis and tumors size (p < 0.05). 8/62 (12.9%) patients met the criteria of locoregional therapies. Conclusion: Advanced HCC was a heterogeneous population in terms of CT findings, liver function tests and PS. Detailed classification of this subgroup could optimize treatment outcomes. Key words: Hepatocellular carcinoma, computed tomography, Child-Pugh, ALBI, locoregional therapy
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
